Toggle light / dark theme

Dr. Derek Yach, Founder, President, and Board Member of The Foundation for a Smoke-Free World (FSFW), joined me on ideaXme (http://radioideaxme.com/) to discuss his group’s work in the core areas of Agriculture and Livelihoods, Industry Transformation, and Health, Science, and Technology (Disclosure — FSFW is funded ~$US1 Billion by Philip Morris International, but take a listen to full story…) — #Ideaxme #Smoking #Vaping #Tobacco #Cessation #AlternativeUses #HarmReduction #WHO #CDC #Health #Wellness #Longevity #Biotechnology #LifeExtension #Aging #IraPastor #Bioquark #Regenerage World Health Organization (WHO) CDC CDC Global United Nations Philip Morris International.


Ira Pastor, ideaXme life sciences ambassador and founder of Bioquark, interviews Dr. Derek Yach, founder, president, and board member of The Foundation for a Smoke-Free World, and passionate advocate for health promotion and disease prevention. Dr Yach’s objective is to end smoking in this generation. We investigated to see how that might be achieved.

Disclosure: The Foundation for a Smoke-Free World has received its initial funding pledge of $80 million USD annually for 12 years, beginning in 2018 from Philip Morris International (PMI) — The Foundation has a nonprofit status as a US 501c3 organization, and by law and policy must operate completely independently from PMI, and cannot engage in activities designed to support PMI’s interests. Further, PMI can have no involvement or say in their work.

Ira Pastor Comments:

The World Health Organization (WHO) estimates that we currently have over 1.1 billion smokers on earth, and that tobacco kills more than 8 million people each year. More than 7 million of those deaths are the result of direct tobacco use while around 1.2 million are the result of non-smokers being exposed to second-hand smoke.

Quantum computers will revolutionize information technology, ushering in an era where certain types of calculations will be performed with almost unimaginable speed. Practical applications will include healthcare disciplines such as molecular biology and drug discovery; big data mining; financial services such as portfolio analysis and fraud detection; and artificial intelligence and machine learning.

The federal government is helping to create an environment in which quantum computing innovation and experimentation can flourish. The National Quantum Initiative Act puts $1.2 billion into the quantum research budgets of the Energy Department, the National Institute of Standards and Technology, NASA and the National Science Foundation. The law also outlines a 10-year plan to accelerate the development of quantum information science and technology applications.

Meanwhile, The White House’s Office of Science and Technology Policy is working to ensure that economic growth opportunities and opportunities for improving the world are baked into quantum policies and systems.

TRENDING: kathy griffin tried to cut in line for COVID test, turns out she had diarrhea after mexico trip

“And if even the smallest transgression of confinement restrictions ends up being a misdemeanor, how will officials handle tens of millions of them?”

Norris pointed out that if police are expected to enforce the curfews, they too could become stricken with coronavirus.

Another important question is the extent to which continued increases in computational capacity are economically viable. The Stanford Index reports a 300,000-fold increase in capacity since 2012. But in the same month that the Report was issued, Jerome Pesenti, Facebook’s AI head, warned that “The rate of progress is not sustainable…If you look at top experiments, each year the cost is going up 10-fold. Right now, an experiment might be in seven figures but it’s not going to go to nine or 10 figures, it’s not possible, nobody can afford that.”

AI has feasted on low-hanging fruit, like search engines and board games. Now comes the hard part — distinguishing causal relationships from coincidences, making high-level decisions in the face of unfamiliar ambiguity, and matching the wisdom and commonsense that humans acquire by living in the real world. These are the capabilities that are needed in complex applications such as driverless vehicles, health care, accounting, law, and engineering.

Despite the hype, AI has had very little measurable effect on the economy. Yes, people spend a lot of time on social media and playing ultra-realistic video games. But does that boost or diminish productivity? Technology in general and AI in particular are supposed to be creating a new New Economy, where algorithms and robots do all our work for us, increasing productivity by unheard-of amounts. The reality has been the opposite. For decades, U.S. productivity grew by about 3% a year. Then, after 1970, it slowed to 1.5% a year, then 1%, now about 0.5%. Perhaps we are spending too much time on our smartphones.

WASHINGTON — Lockheed Martin will acquire the satellite technology assets of Vector by default after a bankruptcy court received no qualified bids by a deadline last week.

In a Feb. 24 filing in the United States Bankruptcy Court for the District of Delaware, lawyers overseeing the bankruptcy proceedings for Vector said that they received no qualifying bids for the company’s GalacticSky software-defined spacecraft technology by a Feb. 21 deadline.

As a result, Lockheed Martin, which provided debtor-in-possession financing when Vector filed for Chapter 11 bankruptcy in December, will obtain the assets with a “stalking horse” bid of $4.25 million, according to the terms of a Jan. 24 filing. That deal will be finalized at a Feb. 28 court hearing.

A Cambridge-based biotech company that is creating a colony of “human” mice is locked in a Tom and Jerry-style fight with a US pharmaceutical giant.

Kymab, which is backed by the Bill and Melinda Gates Foundation and counts fund manager Neil Woodford among its investors, is seeking permission to appeal to the Supreme Court in a row over patents. It follows a ruling by the Court of Appeal earlier this year that Kymab infringed a patent belonging to US company Regeneron. A previous judgment ruled that Regeneron’s patent was insufficient.

The legal tussle relates to Kymab’s “Kymouse” work, in which it manipulates the genome of mice. Kymab removes the genes that make antibodies in mice and replaces them with human antibody genes. This means that.